Figure 1.
Cohort identification of commercially-insured youth (5–17 years old) who were new users of stimulants, 2006–2015.a aData source: IQVIA PharMetrics® Plus, January 2006–December 2015. bAcute myocardial infarction, stroke, ischemic heart disease, heart failure, respiratory arrest, angina pectoris, cardiac dysrhythmias, transient cerebral ischemia, hypertensive disease, cardiovascular tachycardia, palpitations and syncope. cAplastic anemia, cancer, cerebral palsy, congenital immune deficiencies, cystic fibrosis, dialysis/end stage renal disease, Down syndrome, other lethal chromosomal anomalies, fatal metabolic diseases, human immunodeficiency virus (HIV) infection, organ transplant, respiratory failure.